Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
Shen-Cun Fang,1,2 Hai-Tao Zhang,1 Ying-Ming Zhang,1 Wei-Ping Xie2 1Department of Respiratory Medicine Center, Nanjing Chest Hospital, 2Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of...
Main Authors: | Fang S, Zhang H, Zhang Y, Xie W |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-01-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/apatinib-as-post-second-line-therapy-in-egfr-wild-type-and-alk-negativ-peer-reviewed-article-OTT |
Similar Items
-
Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
by: Zeng D, et al.
Published: (2017-08-01) -
Progress in the treatment of solid tumors with apatinib: a systematic review
by: Zhao D, et al.
Published: (2018-07-01) -
Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases
by: Xiaofang Ying, et al.
Published: (2020-04-01) -
Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
by: Jingjing Ge, et al.
Published: (2021-02-01) -
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)